Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 13, 2016 1:13 AM ET

Biotechnology

Company Overview of BIND Therapeutics, Inc.

Company Overview

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specific pharmaceutical characteristics intended to target tumors at tissue, cellular, and molecular levels and to result in superior patient outcomes by enhancing the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The company’s lead drug candidate includes BIND-014, a prostate-specific membrane antigen (PSMA) targeted Accurin that contains docetaxel, which is in Phase II clinical trials for non-small cell lung cancer. It is also developing BIND-510, a ...

325 Vassar Street

Cambridge, MA 02139

United States

Founded in 2006

89 Employees

Phone:

617-491-3400

Fax:

617-491-0351

Key Executives for BIND Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 44
Total Annual Compensation: $334.9K
Chief Medical Officer
Age: 58
Total Annual Compensation: $84.2K
Compensation as of Fiscal Year 2014.

BIND Therapeutics, Inc. Key Developments

BIND Therapeutics, Inc. Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

BIND Therapeutics, Inc. announced that the iNSITE 1 trial in non-small cell lung cancer (NSCLC) with squamous histology is fully enrolled and data is expected to be available by the end of the first quarter of 2016. In addition, the company announced that the iNSITE 2 trial in patients with advanced cervical cancer and head and neck cancer has completed enrollment of at least 20 patients in each cohort in the first stage of the trial. A decision is expected on whether to advance to the second stage of the study for head and neck cancer by the end of the first quarter of 2016 and early in the second quarter of 2016 for the cervical cancer cohort. Lastly, the Company announced that enrollment is being discontinued in the cholangiocarcinoma and bladder cancer cohorts in the iNSITE 2 trial due to slower than anticipated enrollment.

BIND Therapeutics Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at the 2016 Genitourinary Cancers Symposium

BIND Therapeutics, Inc. announced the presentation of complete data from its phase 2 clinical trial of BIND-014, a PSMA-targeted ACCURIN containing docetaxel, in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) who either were or were not exposed to anti-androgens (abiraterone acetate and/or enzalutamide). BIND-014 was clinically active and well-tolerated and the study met its primary endpoint with 71% of patients achieving rPFS of at least 6 months. The complete data are being presented on January 7, 2016 during a poster session at the 2016 Genitourinary Cancers Symposium held in San Francisco. In addition to the primary endpoint, data presented from the trial included measurements of safety and tolerability, objective response rates (ORR), prostate-specific antigen (PSA) response, changes in circulating tumor cells (CTC) and overall survival (OS).

BIND Therapeutics, Inc. Appoints Jonathan Yingling as Chief Scientific Officer

BIND Therapeutics, Inc. announced the appointment of Jonathan Yingling, Ph.D., as Chief Scientific Officer. In this position, Dr. Yingling will be responsible for leading BIND's research and development efforts to identify and pursue new product opportunities where the unique attributes of ACCURINs can be leveraged to provide meaningful improvements in patient care. Dr. Yingling joins BIND from Bristol-Myers Squibb (BMS), where he was vice president, Oncology Discovery and Translational Research. During his tenure at BMS, he was responsible for the oncology research portfolio as well as translational capabilities in oncology and immunoscience, contributing to the discovery and development of potentially transformative medicines in immuno-oncology.

Similar Private Companies By Industry

Company Name Region
Algal Scientific Corporation United States
Inanovate, Inc. United States
MSM Protein Technologies, Inc. United States
JN-International Medical Corporation United States
Kaio Therapy, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BIND Therapeutics, Inc., please visit bindtherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.